rifabutinrifabutin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifabutin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampinrifampin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Side Effect | Severity | Frequency | Notes |
|---|---|---|---|
| Headache | Mild | Common | Often temporary |
| Flushing | Mild | Common | Due to vasodilation |
| Indigestion | Mild | Occasionally | Gastrointestinal discomfort |
| Dizziness | Mild | Less common | Especially when standing up |
rifapentinerifapentine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifapentine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rilzabrutinibrilzabrutinib increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
metronidazolemetronidazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. metronidazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mifepristonemifepristone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mifepristone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. minoxidiltadalafil increases effects of minoxidil by pharmacodynamic synergism.
tadalafil increases effects of minoxidil by pharmacodynamic synergism. mitotanemitotane decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments. mitotane decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nadololtadalafil increases effects of nadolol by pharmacodynamic synergism. Monitor for tadalafil adverse effects if coadministered with moderate CYP3A4 inhibitors.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 5mg | 90 + 6 Pills | 115.91€ 110.39€ | |
| Cialis Generic | 40mg | 10 Pills | 37.79€ 35.99€ | |
| Cialis Generic | 2.5mg | 90 + 6 Pills | 112.43€ 107.08€ | |
| Cialis Generic | 2.5mg | 60 + 4 Pills | 83.43€ 79.46€ | |
| Tadalista Super Active | 20mg | 180 + 20 Pills | 521.59€ 496.75€ | |
| Cialis Generic | 60mg | 360 + 10 Pills | 570.52€ 543.35€ | |
| Cialis Generic | 20mg | 10 Pills | 31.49€ 29.99€ | |
| Tadalista Super Active | 20mg | 90 + 10 Pills | 314.14€ 299.18€ | |
| Cialis Generic | 10mg | 270 + 10 Pills | 308.71€ 294.01€ | |
| Cialis Generic | 2.5mg | 360 + 10 Pills | 260.03€ 247.65€ |
rilzabrutinib increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
rucaparibrucaparib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dosage of CYP3A4 substrates, if clinically indicated. rucaparib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamiderufinamide will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamide will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sacubitril/valsartantadalafil increases effects of sacubitril/valsartan by pharmacodynamic synergism.
pazopanibpazopanib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pazopanib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbitalpentobarbital will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbital will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbitalphenobarbital will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
phenobarbital will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tadalafil increases effects of phenoxybenzamine by pharmacodynamic synergism. phentolaminetadalafil increases effects of phentolamine by pharmacodynamic synergism. tadalafil increases effects of phentolamine by pharmacodynamic synergism. phenytoinphenytoin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tadalafil increases effects of sacubitril/valsartan by pharmacodynamic synergism. Possible additive vasorelaxation, leading to low blood pressure. Coadministration of sepiapterin with drugs affecting nitric oxide-mediated relaxation may cause additive vasodilation and further reduce blood pressure.
tadalafil increases effects of quinapril by pharmacodynamic synergism. ramipriltadalafil increases effects of ramipril by pharmacodynamic synergism. tadalafil increases effects of ramipril by pharmacodynamic synergism. ribociclibribociclib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ribociclib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. silodosintadalafil increases effects of silodosin by pharmacodynamic synergism. tadalafil increases effects of silodosin by pharmacodynamic synergism. sotaloltadalafil increases effects of sotalol by pharmacodynamic synergism. tadalafil increases effects of sotalol by pharmacodynamic synergism. spironolactonetadalafil increases effects of spironolactone by pharmacodynamic synergism. tadalafil increases effects of spironolactone by pharmacodynamic synergism. St John's WortSt John's Wort will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Aspect | Description | Typical Dosage | Duration of Effect |
|---|---|---|---|
| Purpose | Treat erectile dysfunction and BPH | 5 mg or 10 mg | Up to 36 hours |
| Common Brand Names | Cialis, Adcirca | N/A | N/A |
| Administration | Usually taken once a day or as needed | N/A | N/A |
St John's Wort will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Risk of hypotension.tadalafil increases effects of nifedipine by pharmacodynamic synergism. nifedipine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinibnilotinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nimodipinetadalafil increases effects of nimodipine by pharmacodynamic synergism.
tadalafil increases effects of nimodipine by pharmacodynamic synergism. nisoldipinetadalafil increases effects of nisoldipine by pharmacodynamic synergism. tadalafil increases effects of nisoldipine by pharmacodynamic synergism. olmesartantadalafil increases effects of olmesartan by pharmacodynamic synergism. tadalafil increases effects of olmesartan by pharmacodynamic synergism. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. tecovirimattecovirimat will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered. tecovirimat will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. telmisartantadalafil increases effects of telmisartan by pharmacodynamic synergism. tadalafil increases effects of telmisartan by pharmacodynamic synergism. terazosintadalafil increases effects of terazosin by pharmacodynamic synergism.
tadalafil increases effects of nadolol by pharmacodynamic synergism. nafcillinnafcillin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nafcillin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nebivololtadalafil increases effects of nebivolol by pharmacodynamic synergism. tadalafil increases effects of nebivolol by pharmacodynamic synergism.
nefazodonenefazodone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nefazodone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nevirapinenevirapine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nevirapine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipinenifedipine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tadalafil increases effects of terazosin by pharmacodynamic synergism. tetracyclinetetracycline will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tetracycline will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
timololtadalafil increases effects of timolol by pharmacodynamic synergism. tadalafil increases effects of timolol by pharmacodynamic synergism. tipranavirtipranavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
phenytoin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. posaconazoleposaconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. posaconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. prazosintadalafil increases effects of prazosin by pharmacodynamic synergism. tadalafil increases effects of tadalafil in women prazosin by pharmacodynamic synergism. tipranavir will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
tobramycin inhaledtobramycin inhaled and tadalafil both increase nephrotoxicity and/or ototoxicity. Avoid concurrent or sequential use to decrease risk for ototoxicity tobramycin inhaled and tadalafil both increase nephrotoxicity and/or ototoxicity. Avoid concurrent or sequential use to decrease risk for ototoxicity topiramatetopiramate will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
primidoneprimidone will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primidone will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. propranololtadalafil increases effects of propranolol by pharmacodynamic synergism. tadalafil increases effects of propranolol by pharmacodynamic synergism. quinapriltadalafil increases effects of quinapril by pharmacodynamic synergism.